High selenium yeast supplementation (200 mug/d) was evaluated in a double-blind, randomized, placebo-controlled trial. Intention-to-treat analyses assessed the effect on HIV-1 viral load and CD4 count after 9 months of treatment.
Selenium-treated subjects whose serum selenium increase was greater than 26.1 microg/L evidenced excellent treatment adherence, no change in HIV-1 viral load, and an increase in CD4 count.
Daily selenium supplementation can suppress the progression of HIV-1 viral burden and provide indirect improvement of CD4 (a certain type of white cells) count. The results support the use of selenium as a simple, inexpensive, and safe adjunct therapy in HIV spectrum disease.
REFERENCE:
Arch Intern Med. 2007 Jan 22;167(2):148-54.
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
Hurwitz BE1, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, Shor-Posner G, Skyler JS, Schneiderman N.
Selenium-treated subjects whose serum selenium increase was greater than 26.1 microg/L evidenced excellent treatment adherence, no change in HIV-1 viral load, and an increase in CD4 count.
Daily selenium supplementation can suppress the progression of HIV-1 viral burden and provide indirect improvement of CD4 (a certain type of white cells) count. The results support the use of selenium as a simple, inexpensive, and safe adjunct therapy in HIV spectrum disease.
REFERENCE:
Arch Intern Med. 2007 Jan 22;167(2):148-54.
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
Hurwitz BE1, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, Shor-Posner G, Skyler JS, Schneiderman N.
Flux RSS